Trial Profile
A Phase 2 Study to Evaluate the Efficacy and Safety of AQX-1125 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Mediated by the Src Homology-2-domain-containing Inositol 5' Phosphatase [SHIP1] Pathway
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Rosiptor (Primary)
- Indications Interstitial cystitis
- Focus Therapeutic Use
- Acronyms LEADERSHIP
- Sponsors Aquinox Pharmaceuticals
- 04 Aug 2016 Results were presented at the Annual Meeting of the Canadian Urological Association (CUA) 2016, according to an Aquinox Pharmaceuticals media release.
- 10 May 2016 Results assessing plasma and urinary pharmacokinetics (n=35) presented at the 111th Annual Meeting of the American Urological Association
- 10 May 2016 Results presented at the 111th Annual Meeting of the American Urological Association